Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue
✍ Scribed by Valérie Cochen; Maria-Joao Ribeiro; Jean-Paul Nguyen; Jean-Marc Gurruchaga; Gabriel Villafane; Christian Loc'h; Gilles Defer; Yves Samson; Marc Peschanski; Philippe Hantraye; Pierre Cesaro; Philippe Remy
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 833 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
An erratum for this article appears in the January, 2004 issue of Movement Disorders (Mov Disord 2004;12:119).
We compared the striatal uptake of [^18^F]fluorodopa with [^76^Br]‐FE‐CBT, a positron emission tomography (PET) ligand of the dopamine transporter (DAT), which estimates the density of dopamine nerve terminals, in 6 patients with Parkinson's disease grafted with fetal mesencephalic cells. There was no change in DAT ligand binding in the grafted putamen, despite a significant increase of [^18^F]fluorodopa uptake. This finding suggests that the clinical benefit induced by the graft is more related to increased dopaminergic activity than improved dopaminergic innervation in the host striatum and, therefore, that [^18^F]fluorodopa remains the optimal tracer to evaluate grafted PD patients. Further analysis showed that the clinical and [^18^F]fluorodopa uptake changes after the grafts were correlated with the number of ventral mesencephalae used for implantation. © 2003 Movement Disorder Society
📜 SIMILAR VOLUMES
## Abstract See 10.1002/mds.20313 for a reply to this letter.
## Abstract See 10.1002/mds.20304 for the original article to which this letter refers.
## Abstract Increasing evidence suggests that neuroinflammation is an active process in Parkinson's disease (PD) that contributes to ongoing neurodegeneration. PD brains and experimental PD models show elevated cytokine levels and up‐regulation of inflammatory‐associated factors as cyclo‐oxygenase‐
## Abstract The Unified Parkinson's Disease Rating Scale (UPDRS) is the primary outcome measure in most clinical trials of Parkinson's disease (PD) therapeutics. Each subscore of the motor section (UPDRS III) compresses a wide range of motor performance into a coarse‐grained scale from 0 to 4; the